Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUNDThe KRAS proto-oncogene is among the most frequently mutated genes in cancer, yet for 40 years it remained an elusive therapeutic target. Recently, allosteric inhibitors that covalently bind to KRAS G12C mutations have been approved for use in lung adenocarcinomas. Although responses are observed, they are often short-lived, thus making in-depth characterization of the mechanisms of resistance of paramount importance.METHODSHere, we present a rapid-autopsy case of a patient who had a KRASG12C-mutant lung adenocarcinoma who initially responded to a KRAS G12C inhibitor but then rapidly developed resistance. Using deep-RNA and whole-exome sequencing comparing pretreatment, posttreatment, and matched normal tissues, we uncover numerous mechanisms of resistance to direct KRAS inhibition.RESULTSIn addition to decreased KRAS G12C-mutant allele frequency in refractory tumors, we also found reactivation of the MAPK pathway despite no new mutations in KRAS or its downstream mediators. Tumor cell-intrinsic and non-cell autonomous mechanisms included increased complement activation, coagulation, and tumor angiogenesis, and several lines of evidence of immunologic evasion.CONCLUSIONTogether, our findings reveal numerous mechanisms of resistance to current KRAS G12C inhibitors through enrichment of clonal populations, KRAS-independent downstream signaling, and diverse remodeling of the tumor microenvironment.FUNDINGRichard and Fran Duley, Jimmy and Kay Mann, the NIH, and the North Carolina Biotechnology Center.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Supporting this hypothesis, a recent study by Tsai et al. reported an upregulation of YAP1 activity in tumor tissues from patients who developed resistance to KRAS inhibitors (10).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, some patients selected for these trials may have preexisting multidrug resistance (9, 37, 74), which could contribute to treatment failure.”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“correlative studies conducted in other KRASG12C-mutant tumor types treated with these inhibitors have demonstrated the emergence of pleiotropic resistance through both cell autonomous and non-cell autonomous mechanisms76–78.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The number of CD8+ T cells, macrophages, and DCs in KRAS (G12C) tumors increased significantly after 5 days of AMG510 treatment.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [149]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and others have recently described mechanisms of acquired resistance in patients with lung and colorectal cancer (CRC) treated with KRASG12C inhibitors, including mutations in KRAS or other RTK–RAS–MAPK pathway effectors, adaptive signaling alterations, and histologic transformation to drug-resistant cell states (14, 18–24).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [24]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“We tested genes for differential expression in DESeq2 (26) (v1.”
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 1×
“We tested for C5 ontology gene set, C6 oncogenic signature gene sets, and Hallmark gene sets (31).”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · cited 1×
“2 (24) with parameters set as follows: –outSAMtype BAM Unsorted –quantMode TranscriptomeSAM.”
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458 · cited 1×
“differentially expressed gene sets using limma (moderated t-test, two-sided) (28) (v3.”
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621 · cited 1×
“were created using ANNOVAR v2019Oct24 (39), using their suggest-”
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807 · cited 1×
“Gene set collections were downloaded from the MSigDB website (29, 30) (version 6.”
Salmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700
Molecular signatures database (MSigDB) 3.0
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111 · cited 1×
“Gene set collections were downloaded from the MSigDB website (29, 30) (version 6.”
Cited by
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Singhal, A., Li, B. T., & O’Reilly, E. M. (2024) · Nature Medicine · doi:10.1038/s41591-024-02903-0 · Cited by 332
“Interestingly, induction of EMT was a dominant mechanism of resistance in a rapid-autopsy case of a patient with lung adenocarcinoma who had relapse of disease while receiving sotorasib 64 .”
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
“…mechanisms of acquired resistance in patients with lung and colorectal cancer (CRC) treated with KRAS G12C inhibitors, including mutations in KRAS or other RTK–RAS–MAPK pathway effectors, adaptive signaling alterations, and histologic transformation to drug-resistant cell states (14, 18–24).”
BackgroundTargeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231
“Simultaneously, the expression of molecules for interferon signaling, chemokine production, and antigen processing increased [149].”
BackgroundInfluentialDrugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Tong, X., Patel, A. S., Kim, E., Li, H., Chen, Y., Li, S., Liu, S., Dilly, J., Kapner, K. S., Zhang, N., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.012 · Cited by 142
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 146
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
Lv, X., Lu, X., Cao, J., Luo, Q., Ding, Y., Peng, F., Pataer, A., Lu, D., Han, D., Malmberg, E., et al. (2023) · Science · doi:10.1126/science.abn4180 · Cited by 123
Feng, J., Hu, Z., Xia, X., Liu, X., Lian, Z., Wang, H., Wang, L., Wang, C., Zhang, X., & Pang, X. (2023) · Oncogene · doi:10.1038/s41388-023-02676-9 · Cited by 95
“Clinical studies have revealed that sotorasib demonstrates satisfactory efficacy in patients with non–small cell lung cancer, with a satisfactory response rate [12, 13].”
BackgroundTEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
Edwards, A. C., Stalnecker, C. A., Jean Morales, A., Taylor, K. E., Klomp, J. E., Klomp, J. A., Waters, A. M., Sudhakar, N., Hallin, J., Tang, T. T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2994 · Cited by 91
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 82
“Along with the rapid development of drug resistance, heterogeneous resistant mechanisms involving reactivation of MAPK and PI3K-AKT-mTOR signaling, epithelial-tomesenchymal transition (EMT), immune evasion, metabolic rewiring, loss of KRAS allele and copy number were observed in multiple lesions derived from different…”
BackgroundDormancy, stemness, and therapy resistance: interconnected players in cancer evolution
Francescangeli, F., Angelis, M. L. D., Rossi, R., Cuccu, A., Giuliani, A., Maria, R. D., & Zeuner, A. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10092-4 · Cited by 114
“Treatmentinduced changes in tumor cells included bypassing KRAS inhibition, metabolic reprogramming, and EMT, while changes in the TME consisted of increased coagulation, angiogenesis, and immune suppression [165].”
BackgroundResponse and Resistance to RAS Inhibition in Cancer
Ebright, R. Y., Dilly, J., Shaw, A. T., & Aguirre, A. J. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0349 · Cited by 83
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Nokin, M., Mira, A., Patrucco, E., Ricciuti, B., Cousin, S., Soubeyran, I., José, S. S., Peirone, S., Caizzi, L., Michelina, S. V., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51828-2 · Cited by 76
“The heterogeneity, as well as the presence of multiple subclonal events of such acquired mechanisms, poses dif fi culties in overcoming resistance to KRAS G12C covalent inhibitors 26 .”
KRAS: the Achilles’ heel of pancreas cancer biology
Drizyte‐Miller, K., Talabi, T., Somasundaram, A., Cox, A. D., & Der, C. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191939 · Cited by 73
“Some of these include transcriptional reprogramming that changes cellular states such as epithelial-to-mesenchymal transition (164), activation of YAP/TAZ signaling (167), adeno-to-squamous cell carcinoma transition (87), and mucinous differentiation (170).”
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
Skoulidis, F., Li, B. T., Langen, A. J. D., Hong, D. S., Léna, H., Wolf, J., Dy, G. K., Fontecedro, A. C., Tomasini, P., Velcheti, V., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03732-5 · Cited by 68
“Furthermore, tumor cell-extrinsic factors, including innate and adaptive host immune responses and remodeling of the tumor microenvironment (TME), were reported to modulate responses to KRAS extinction or inhibition 27,28 .”
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance
Sattler, M., Mohanty, A., Kulkarni, P., & Salgia, R. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2022.10.001 · Cited by 54
Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
Salmón, M., Álvarez-Díaz, R., Fustero-Torre, C., Brehey, O., Lechuga, C. G., Sanclemente, M., Fernández-García, F., López-García, A., Martín-Guijarro, M. C., Rodríguez-Perales, S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164413 · Cited by 52
“Moreover, increased activation of xenobiotic metabolism was also recently reported in sotorasib-resistant lesions from a patient autopsy (42).”
USP7 deubiquitinates KRAS and promotes non-small cell lung cancer
Huang, B., Cao, D., Yuan, X., Xiong, Y., Chen, B., Wang, Y., Niu, X., Tian, R., & Huang, H. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114917 · Cited by 54
More to the RAS Story: KRAS G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS G12C
Lietman, C. D., Johnson, M. L., McCormick, F., & Lindsay, C. R. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351333 · Cited by 44
Overcoming KRAS-Mutant Lung Cancer
Luo, J., Ostrem, J. M. L., Pellini, B., Imbody, D., Stern, Y. E., Solanki, H. S., Haura, E. B., & Villaruz, L. C. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_360354 · Cited by 59
Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy
Boumelha, J., Molina‐Arcas, M., & Downward, J. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3655 · Cited by 46
Yang, N., Fan, Z., Sun, S., Hu, X., Mao, Y., Jia, C., Cai, X., Xu, T., Li, B., Li, Y., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115857 · Cited by 44
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Batrash, F., Kutmah, M., & Zhang, J. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00453-8 · Cited by 43
“Finally, as KRAS G12C mutation is involved in a proinflammatory TME, dysregulated cell cycle and autophagy, combinatorial efficacy with immunotherapy, chemotherapy and autophagy inhibition is anticipated [5, 42, 91, 93–95].”
BackgroundKRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
Rosell, R., Codony‐Servat, J., González, J., Santarpía, M., Jain, A. S., Shivamallu, C., Wang, Y., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Nilsson, J. A., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104228 · Cited by 47
Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments
Ji, J., Wang, C., & Fakih, M. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s340392 · Cited by 39
“Histologic evaluation in a rapid-autopsy case in a patient with KRAS inhibitor resistant NSCLC also observed non-cell autonomous mechanisms of resistance including remodeling of the tumor microenvironment.(39)”
BackgroundRAS degraders: The new frontier for RAS-driven cancers
Escher, T. E., & Satchell, K. J. F. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.017 · Cited by 42
Ramalingam, P. S., Balakrishnan, P., Rajendran, S., Jothi, A., Rajasekaran, R., & Arumugam, S. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45030137 · Cited by 36
“Accumulating pieces of evidence report that the KRAS G12C inhibitors such as Sotorasib (AMG 510), ARS-1620, and Adagrasib (MRTX849) are becoming resistant in non-small-cell-lung-cancer (NSCLC) and colorectal-cancer (CRC) patients [44,45].”
BackgroundYang, W., Zhang, M., Zhang, T.-X., Liu, J.-H., Hao, M.-W., Yan, X., Gao, H., Lei, Q.-Y., Cui, J., & Zhou, X. (2024) · JCI Insight · doi:10.1172/jci.insight.178535 · Cited by 31
“…(such as neuroblastoma RAS viral oncogene homolog [ NRAS ], v-Raf murine sarcoma viral oncogene homolog B [ BRAF ], v-Raf-1 murine leukemia viral oncogene homolog 1 [ RAF1 ], tyrosine-protein kinase Met [ MET ], or phosphatase and tensin homolog [ PTEN ]) within the RAS signaling pathway (8–10).”
InfluentialA first-in-class EGFR-directed KRAS G12V selective inhibitor
Stanland, L. J., Huggins, H. P., Sahoo, S. S., Porrello, A., Chareddy, Y. S., Azam, S. H., Perry, J. L., Pallan, P. S., Whately, K. M., Edatt, L., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.016 · Cited by 42
Self-citationPrahallad, A., Weiss, A., Voshol, H., Kerr, G., Sprouffske, K., Yuan, T., Ruddy, D., Meistertzheim, M., Kazic-Legueux, M., Kottarathil, T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1127 · Cited by 30
“…have also been discussed as promoting KRAS independence by metabolic reprogramming, and also by triggering the epithelial-to-mesenchymal transition (53); YAP pathway activation was recently identi fi ed as a potential adaptive mechanism in a patient with polymorphic resistance to sotorasib (54).”
BackgroundNon-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit
Ning, W., Marti, T. M., Dorn, P., & Peng, R.-W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1004669 · Cited by 29
“, vascular endothelial growth factor A (VEGFA), via cyclooxygenase 2 (COX2) (44) and activation of tumor angiogenesis and coagulation pathways leads to adaption to sotorasib (45).”
BackgroundInfluentialSRC kinase drives multidrug resistance induced by KRAS-G12C inhibition
Song, X., Zhou, Z., Elmezayen, A., Wu, R., Yu, C., Gao, B., Minna, J. D., Westover, K. D., Zeh, H. J., Kroemer, G., et al. (2024) · Science Advances · doi:10.1126/sciadv.adq4274 · Cited by 26
Tanaka, N., & Ebi, H. (2024) · Cancer Science · doi:10.1111/cas.16441 · Cited by 30
“EMT can lead to KRAS independency in lung and pancreatic cancer, and the mesenchymal phenotype was shown to contribute to both intrinsic and acquired resistance to KRAS G12C inhibitors in lung cancer in preclinical models as well as patient samples resistant to sototasib [19, 37].”
Targeting therapy-persistent residual disease
Sun, X., Wu, L. F., Altschuler, S. J., & Hata, A. N. (2024) · Nature Cancer · doi:10.1038/s43018-024-00819-9 · Cited by 29
Advances in the treatment of KRASG12C mutant non–small cell lung cancer
Shaverdashvili, K., & Burns, T. F. (2025) · Cancer · doi:10.1002/cncr.35783 · Cited by 32
“61”
Ramalingam, P. S., Priyadharshini, A., Emerson, I. A., & Arumugam, S. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1107128 · Cited by 33
“Accumulating pieces of evidence report that sotorasib is becoming resistant among NSCLC, pancreatic ductal adenocarcinoma, and colorectal adenocarcinoma patients bearing KRAS G12C mutation and even resulting in hepatotoxicity (31, 32).”
BackgroundDirect GDP-KRAS G12C inhibitors and mechanisms of resistance: the tip of the iceberg
Rosen, J. C., Sacher, A. G., & Tsao, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231160141 · Cited by 24
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 28
“…mutations in other RTKs and RAS/MAPK pathways members, MET amplification, activating mutations in NRAS , BRAF , MAP2K1 , and RET , oncogenic fusions involving ALK , RET , BRAF , and FGFR3 , inactivation mutations in NF1 and PTEN , and histologic transformation have been reported [135, 136].”
Leveraging Sponsorship Through Cause Related Marketing: Complementarities and Conflicts
Speed, R., & Polonsky, M. J. (2001) · European Journal of Marketing · Cited by 20
Ramalingam, P. S., & Arumugam, S. (2023) · Medical Oncology · doi:10.1007/s12032-023-02160-0 · Cited by 21
“In addition, the first KRAS G12C inhibitor Sotorasib (AMG510), approved by FDA is becoming resistant in PDAC and NSCLC patients in real-world settings [11, 20].”
BackgroundZhang, F., Wang, B., Wu, M., Zhang, L., & Ji, M. Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1509173 · Cited by 28
Computational design and validation of effective siRNAs to silence oncogenic KRAS
Ramalingam, P. S., & Arumugam, S. (2023) · 3 Biotech · doi:10.1007/s13205-023-03767-w · Cited by 18
Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions
Shang, Y., Fu, S., Hao, Q., Ying, H., Wang, J., & Shen, T. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107092 · Cited by 18
Manabe, T., & Bivona, T. G. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156891 · Cited by 17
Zhang, Y., Liu, L., Pei, J., Ren, Z., Deng, Y., & Yu, K. (2024) · Oncogene · doi:10.1038/s41388-023-02924-y · Cited by 19
“Moreover, many resistant tumors showed signi fi cant activation of the AKT/mTOR signaling pathways and downregulated multiple immune signals associated with activation of antitumor immunity, suggesting that immune escape could be a critical feature of acquired resistance to KRAS inhibitors [8, 9].”
BackgroundCurrent perspectives of KRAS in non-small cell lung cancer
Harris, E., & Thawani, R. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101106 · Cited by 18
Bontoux, C., Hofman, V., Brest, P., Ilié, M., Mograbi, B., & Hofman, P. M. (2022) · Cancers · doi:10.3390/cancers14071628 · Cited by 20
The Discovery of Cryptic Pockets Increases the Druggability of “Undruggable” Proteins
Mou, M., Yang, W., Huang, G., Yang, X., Zhang, X. L., Kandegama, W., Ashby, C. R., Hao, G., & Gao, Y. (2025) · Medicinal Research Reviews · doi:10.1002/med.70001 · Cited by 15
“As expected, resistance has occurred in patients after following treatment with KRAS G12C inhibitors [193].”
KRASG12D drives immunosuppression in lung adenocarcinoma through paracrine signaling
Opsahl, E. L. L., Barravecchia, I., McLintock, E., Lee, J. M., Ferris, S. F., Espinoza, C. E., Hinshaw, R., Cavanaugh, S., Robotti, M., Rober, L., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.182228 · Cited by 16
“While these are exciting developments, the prospect of resistance to targeted therapy is real; resistance already has been described for G12C inhibitors (4), with some instances involving sotorasib linked to the remodeling of the tumor microenvironment (5, 6).”
Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions
Peng, C., & Oberstein, P. E. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01352-2 · Cited by 14
“These include alternative MAPK pathway activation, gene fusions, and microsatellite unstable tumors (see immune section below) [ 69 ]. downstream activations of the MAPK pathway as well as activations of alternative pathways such as AKT [ 55 – 57 ].”
WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer
Yamamoto, G., Tanaka, K., Kamata, R., Saito, H., Yamamori-Morita, T., Nakao, T., Liu, J., Mori, S., Yagishita, S., Hamada, A., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2024.217414 · Cited by 11
Inverted chimeric RNAi molecules synergistically cotarget MYC and KRAS in KRAS-driven cancers
Chareddy, Y. S., Huggins, H. P., Sahoo, S. S., Stanland, L. J., Gutierrez-Ford, C., Whately, K. M., Edatt, L., Azam, S. H., Fleming, M. C., Im, J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci187204 · Cited by 12
Self-citationKale, R. R., Samant, C., Nandakumar, K., Pai, K. S. R., & Bhonde, M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151688 · Cited by 12
Solanki, H. S., Shah, H., Imbody, D. J., Desai, B., Kato, R., Miroshnychenko, D., Stern, Y. E., Majumder, A., Sarcar, B., Xieraili, A., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0600 · Cited by 12
Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells
Lee, C., Yi, J., Park, J., Ahn, B., Won, Y.-W., Jeon, J., Lee, B. J., Cho, W. J., & Park, J. W. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06436-9 · Cited by 9
Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer
Guo, M. Z., Marrone, K. A., Spira, A. I., & Rosner, S. (2023) · Future Oncology · doi:10.2217/fon-2022-1106 · Cited by 11
Baird, L., Zhang, L., Hidaka, T., Xi, L., Wang, K., Tateno, K., Iso, T., Suzuki, T., Kumada, K., Katsuoka, F., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03162-7 · Cited by 10
“Data were sourced from Tsai et al. 2022. o Immunoblot showing signi fi cant stabilization of the NRF2 protein in wild type MEFs (WT), but not Keap1-C151S mutant MEFs (C151S), in response to the indicated concentrations of Adagrasib (Adag). p Model showing that electrophilic KRAS-G12C inhibitor drugs…”
Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
Novoplansky, O., Jagadeeshan, S., Prasad, M., Yegodayev, K. M., Marripati, D., Shareb, R. A., Greenshpan, Y., Mathukkada, S., Lulu, T. B., Bhattacharya, B., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03227-0 · Cited by 8
“Although resistance to these inhibitors has already emerged as a serious concern [18, 21, 22, 24, 66–72], it is essential to have a comprehensive understanding of the underlying resistance mechanisms (both intrinsic and extrinsic).”
Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors
Stern, Y. E., Ghosh, P., Peroza, J., Solanki, H. S., Imbody, D. J., Bridenstine, L., Pandurangan, T., Frydman, S. M., Nickens, K. N., Walker-Mimms, H. L., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0450 · Cited by 7
Theardy, M. S., Takeda, M., Sorokin, A., Chen, S., Yang, Z., Wang, X., Kanikarla, P., Coker, O., Nguyen, P., Wei, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102253 · Cited by 6
“4,8,20,21 8, 22– 25 Our study similarly multiple RTKs in AMG510-R AMG510-R Previously, we demonstrated that SDC1 plays a critical role for oncogenic KRAS-mediated macropinocytosis, 12 a nutrient salvage process that supports oncogenic growth.”
Liu, S., Jiang, Y., Fu, Y., Wang, S., Fu, R., Gao, M., Zhao, Y., Chen, S., Yang, Y., Yang, W., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012886 · Cited by 7
“19 Consistent with our observations, during the initiation and development of resistance, we observed a dramatic decrease in CD8 + T cell abundance, including T CM and T EM , activation of CD8 + T cells, and functionality of cytotoxic CD8 + T cells.”
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Wu, C., Li, W., Chen, M., Zhang, Q., Xu, T., Ma, Y., Liu, W., Wang, Z., Wang, X., Li, J., et al. (2023) · Holistic Integrative Oncology · doi:10.1007/s44178-023-00032-1 · Cited by 7
“Actually, RAS is at the center of the complex RTKRAS-MAPK signaling cascade, therefore acquired mutations or reactivation of bypass or upstream pathways might also impact the efficacy of KRASG12C inhibitors [22, 30].”
BackgroundKRAS and NRAS Translation Is Increased upon MEK Inhibitors-Induced Processing Bodies Dissolution
Vidal-Cruchez, O., Nicolini, V. J., Rete, T., Rezzonico, R., Lacoux, C., Fassy, J., Jacquet, K., Roméo, B., Ventujol, C., Hubstenberger, A., et al. (2023) · Cancers · doi:10.3390/cancers15123078 · Cited by 8
Lee, A. T., & Nagasaka, M. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s492126 · Cited by 7
The Oxidative Drug Combination for Suppressing KRAS G12D Inducible Tumour Growth
Бегимбетова, Д., Kukanova, А., Fazyl, F., Manekenova, K., Омаров, Т. М., Burska, A. N., Khamijan, M., Gulyayev, A., Yermekbayeva, B., Макишев, А. К., et al. (2022) · BioMed Research International · doi:10.1155/2022/9426623 · Cited by 7
Zhang, J., Zhang, J., Leung, E. L., & Yao, X. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2178419 · Cited by 6
“Successively, promoting tumor microenvironment remodeling may increase the efficacy of KRAS G12 inhibitors and overcome drug resistance [24,42] (Figure 1D).”
BackgroundAdvances on drug therapy for KRAS-mutant non-small-cell lung cancer
Tian, T., & Li, W. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102668 · Cited by 4
“…patients who relapsed during sotorasib treatment, epithelial-mesenchymal transition (EMT) was found to be the main mechanism of resistance[35]; In addition, new preclinical studies have also observed that lung adenocarcinoma transformed into type I alveolar-like state[36]or squamous cell…”
Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations
Deng, J., Shen, S., Huang, L., Xu, F., Huang, W., Huang, C., Zhang, Z., Liu, T., Tan, Y., & Li, Z. (2026) · Nature Communications · doi:10.1038/s41467-026-71093-9 · Cited by 5
Faber, E. B., Baca, Y., Xiu, J., Walker, P., Manji, G. A., Gholami, S., Saeed, A., Prakash, A., Botta, G. P., Sohal, D. P. S., et al. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100042 · Cited by 5
“36 Similarly, resistance to KRAS G12C inhibitors has been observed in CRC driven by this particular KRAS mutation, underscoring the importance of characterizing the TME of each KRAS -mutant isoform, as treatment may need to be personalized depending on the driving mutation and resistance mechanisms.”
Lu, X., Qin, J., Dong, S., Yuan, Y., Zhang, Z., Zhang, B., Chen, X., Gan, X., Liang, H., & Liu, F. (2026) · Biomarker Research · doi:10.1186/s40364-026-00937-9 · Cited by 3
Pancreatic Cancer-Secreted Proteins: Targeting Their Functions in Tumor Microenvironment
Cammarota, A. L., Falco, A., Basile, A., Molino, C., Chetta, M., D’Angelo, G., Marzullo, L., Marco, M. D., Turco, M. C., & Rosati, A. (2023) · Cancers · doi:10.3390/cancers15194825 · Cited by 5
“This limited response was previously observed in lung cancer patients and was characterized by immunological evasion through tumor cell-intrinsic and non-cell autonomous pathways inducing drug resistance [22].”
BackgroundIntratumor heterogeneity in KRAS signaling shapes treatment resistance
Petrenko, O., Kirillov, V., D’Amico, S., & Reich, N. C. (2024) · iScience · doi:10.1016/j.isci.2024.111662 · Cited by 4
Meraz, I. M., Wu, S., Xu, Y., Gao, L., Feng, M., Ren, C., Song, R., Zhang, R., Wang, Q., Xi, Y., et al. (2025) · eLife · doi:10.7554/elife.106875.1 · Cited by 6
Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance
Luo, X., Zhou, F., Tang, Y., Liu, X., Xiao, R., Gu, M., Bai, J., Jiang, D., Yang, G., You, L., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003776 · Cited by 2
“[237] Moreover, the “immune cold” TME prevents the immune system activation necessary for proper ICIs activity, which leads to a poor response to ICIs.”
Yang, H., Zhu, A., Niu, Y., Ma, W., Xu, K., Jia, Y., Xu, W., Zhao, B., Zhang, E., Jia, J., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70490 · Cited by 3
Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer
Zhu, L., Jia, X., Xu, L., Chen, L., Fu, X., Yan, H., Ai, B., & Peng, S. (2025) · iScience · doi:10.1016/j.isci.2025.114429 · Cited by 4
“74 Mechanistically, STK11 loss orchestrates this state through dual metabolic and epigenetic reprogramming: it upre-gulates MCT-4 to enhance lactate efflux, which engages GPR81 on immune cells to promote M2 polarization and T cell dysfunction, 75 while concurrently silencing the STING pathway via…”
Robb, R. N., Ackermann, S. E., Degan, S. E., Taylor, K. E., Yang, R. Y., Marler, A. Z., Calvert, V. S., Pierobon, M., Lyons, S. P., Barker, N. K., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0731 · Cited by 2
Xu, Z., Wang, W., Liu, L., & Lou, W. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188751 · Cited by 3
Megid, R., Ribeiro, G., Gomes, I. N. F., Laus, A. C., Leal, L. F., da Silva, L. S., Ariwoola, A.-B. A., Dias, J. M., Reis, R. M., & Oliveira, R. J. D. S. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1537523 · Cited by 3
Development of highly potent and selective oncogenic KRASG12D PROTAC degraders
Mao, Y., Wei, P., Wei, T., Wang, Y., Qi, Z., Cai, X., Jia, C., Zhao, Z., Li, B., Qiao, M., et al. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100296 · Cited by 4
Targeting RAS for Cancer Treatment: What a Long, Strange Trip It's Been
Cox, A. D., & Der, C. J. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-071024-082459 · Cited by 1
KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers
Yan, M., Liu, K., Xu, J., Liu, Y., Ji, L., & Zhang, S. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02659-w · Cited by 1
“A detailed genetic analysis from the autopsy of a patient with KRAS [G12C]-mutant NSCLC, who experienced relapse while on sotorasib treatment, revealed that EMT activation was the primary mechanism of resistance to direct KRAS [G12C] inhibition [5, 143].”
Mutant-Selective T-cell Receptor Therapy for Solid Tumors
Parry, S. R., Jang, C., Leal, A., & Punekar, S. R. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0894 · Cited by 1
Lu, D., Osgood, T., Ma, S., Zhang, H., Kanke, M., Tan, J. A., Paudel, S. N., Zhou, H., Estrada, J., Yamawaki, T., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0794 · Cited by 1
“Inhibition of KRAS is cytostatic and allows cancer cells to influence their environment by activating DNA damage responses (9, 10) and stimulating the production of extracellular matrix (ECM) proteins (11), growth factors, and immune-modulating cytokines (12, 13).”
KRAS combination strategies: How well aligned is clinical and preclinical research?
Nadal, E., Ambrogio, C., Santamaría, D., & Lindsay, C. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00018-8 · Cited by 2
Data from Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy
Boumelha, J., Molina‐Arcas, M., & Downward, J. (2023) · doi:10.1158/1078-0432.c.6982714 · Cited by 1
Challenges and opportunities of emerging mechanisms of resistance to KRASG12C inhibitors
Cecchini, M., & LoRusso, P. M. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.009 · Cited by 1
Meraz, I. M., Wu, S., Xu, Y., Gao, L., Feng, M., Ren, C., Song, R., Zhang, R., Wang, Q., Xi, Y., et al. (2026) · eLife · doi:10.7554/elife.106875 · Cited by 2
Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, M. V., Araújo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M. D., Minuti, G., et al. (2023) · doi:10.1158/2159-8290.23310275
Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, M. V., Araújo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M. D., Minuti, G., et al. (2023) · doi:10.1158/2159-8290.23310275.v1
Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, M. V., Araújo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M. D., Minuti, G., et al. (2023) · doi:10.1158/2159-8290.23641387
Targeted Therapies for Pancreatic Cancer
Maitra, A. (2023) · Wiley eBooks · doi:10.1002/9781119876007.ch151
Prahallad, A., Weiss, A., Voshol, H., Kerr, G., Sprouffske, K., Yuan, T. L., Ruddy, D. A., Meistertzheim, M., Kazic-Legueux, M., Kottarathil, T., et al. (2023) · doi:10.1158/0008-5472.c.6982749
Prahallad, A., Weiss, A., Voshol, H., Kerr, G., Sprouffske, K., Yuan, T. L., Ruddy, D. A., Meistertzheim, M., Kazic-Legueux, M., Kottarathil, T., et al. (2023) · doi:10.1158/0008-5472.c.6982749.v1
Data from Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy
Boumelha, J., Molina‐Arcas, M., & Downward, J. (2023) · doi:10.1158/1078-0432.c.6982714.v1
Opsahl, E. L. L., Baliira, R. K., Barravecchia, I., McLintock, E., Lee, J. M., Ferris, S. F., Espinoza, C. E., Hinshaw, R., Cavanaugh, S., Robotti, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.16.568090
“This has been observed with Sotorasib [4, 7] and there is concern that resistance to MRTX1133 and other KRAS inhibitors will also develop.”
BackgroundConclusions: the future of RAS drug discovery
Gill, A. L., & Shokat, K. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00009-7
Metadata
- Authors
- Tsai, Y. S., Woodcock, M. G., Azam, S. H., Thorne, L. B., Kanchi, K. L., Parker, J. S., Vincent, B. G., & Pecot, C. V.
- Affiliations
- UNC Lineberger Comprehensive Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Pecot, Chad V.
- Venue
- Journal of Clinical Investigation
- Published
- 2022-02-15
- Volume
- 132
- Issue
- 4
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC8843735
- OpenAlex
- W4205097199
- Cited by
- 103
- References
- 43
- Citations by year
- 2026: 13 · 2025: 25 · 2024: 26 · 2023: 28 · 2022: 11
- FWCI
- 14.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA215075,R01CA258451,1R41CA246848)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS G12C, KRAS inhibitors, drug resistance, lung adenocarcinoma, MAPK pathway reactivation, tumor microenvironment, complement activation, coagulation, tumor angiogenesis, clonal populations, allele frequency, autopsy
- MeSH terms
- Adenocarcinoma of Lung, Humans, Lung Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Amino Acid Substitution, Mutation, Missense, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.